Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Garren

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Idrugs : the Investigational Drugs Journal|December 15, 2010
Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USAHideki Garren
Idrugs : the Investigational Drugs Journal|November 4, 2010
Gene Based Vaccines: Optimising Development and Delivery - A marcus evans ConferenceHideki Garren
Expert Review of Vaccines|September 3, 2009
DNA vaccines for autoimmune diseasesHideki Garren
Expert Opinion on Biological Therapy|September 9, 2008
A DNA vaccine for multiple sclerosisHideki Garren
Results and Problems in Cell Differentiation|September 15, 2010
Multiple sclerosis therapies: molecular mechanisms and futurePaulo Fontoura, Hideki Garren
International Reviews of Immunology|December 2, 2005
Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptidesPaulo Fontoura, Hideki Garren, Lawrence Steinman
Clinical Immunology (Orlando, Fla.)|May 4, 2002
Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune diseaseWilliam H Robinson, Hideki Garren, Paul J Utz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 22, 2003
An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systemsPeggy P Ho, Paulo Fontoura, Pedro J Ruiz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2002
Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factorAnnette Langer-Gould, Hideki Garren, Amy Slansky, et al.
Journal of Neurology|May 5, 2016
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept studyEva Havrdová, Anna Belova, Alla Goloborodko, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Idrugs : the Investigational Drugs Journal|December 15, 2010
Biological Therapeutics Research and Development--GTCbio's Fifth Annual Conference. October 20-22, 2010, San Francisco, CA, USAHideki Garren
Idrugs : the Investigational Drugs Journal|November 4, 2010
Gene Based Vaccines: Optimising Development and Delivery - A marcus evans ConferenceHideki Garren
Expert Review of Vaccines|September 3, 2009
DNA vaccines for autoimmune diseasesHideki Garren
Expert Opinion on Biological Therapy|September 9, 2008
A DNA vaccine for multiple sclerosisHideki Garren
Results and Problems in Cell Differentiation|September 15, 2010
Multiple sclerosis therapies: molecular mechanisms and futurePaulo Fontoura, Hideki Garren
International Reviews of Immunology|December 2, 2005
Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptidesPaulo Fontoura, Hideki Garren, Lawrence Steinman
Clinical Immunology (Orlando, Fla.)|May 4, 2002
Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune diseaseWilliam H Robinson, Hideki Garren, Paul J Utz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 22, 2003
An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systemsPeggy P Ho, Paulo Fontoura, Pedro J Ruiz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2002
Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis: evidence for a suppressive pregnancy-related serum factorAnnette Langer-Gould, Hideki Garren, Amy Slansky, et al.
Journal of Neurology|May 5, 2016
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept studyEva Havrdová, Anna Belova, Alla Goloborodko, et al.
Pageof 4